167 related articles for article (PubMed ID: 19597740)
1. Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells.
Klettner AK; Kruse ML; Meyer T; Wesch D; Kabelitz D; Roider J
Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1601-8. PubMed ID: 19597740
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.
Klettner A; Recber M; Roider J
Graefes Arch Clin Exp Ophthalmol; 2014 Oct; 252(10):1593-8. PubMed ID: 25047874
[TBL] [Abstract][Full Text] [Related]
4. VEGF antagonists decrease barrier function of retinal pigment epithelium in vitro: possible participation of intracellular glutathione.
Miura Y; Klettner A; Roider J
Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4848-55. PubMed ID: 20435596
[TBL] [Abstract][Full Text] [Related]
5. Minimal effects of VEGF and anti-VEGF drugs on the permeability or selectivity of RPE tight junctions.
Peng S; Adelman RA; Rizzolo LJ
Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):3216-25. PubMed ID: 20042644
[TBL] [Abstract][Full Text] [Related]
6. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways.
Klettner A; Roider J
Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4523-7. PubMed ID: 18441313
[TBL] [Abstract][Full Text] [Related]
7. Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro.
Parisi L; Fuhrer R; Zinkernagel M; Enzmann V
Ophthalmologica; 2019; 241(3):137-142. PubMed ID: 30001546
[TBL] [Abstract][Full Text] [Related]
8. Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells.
Chae JB; Rho CR; Shin JA; Lyu J; Kang S
Korean J Ophthalmol; 2018 Aug; 32(4):328-338. PubMed ID: 30091312
[TBL] [Abstract][Full Text] [Related]
9. Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro.
Terasaki H; Sakamoto T; Shirasawa M; Yoshihara N; Otsuka H; Sonoda S; Hisatomi T; Ishibashi T
Retina; 2015 May; 35(5):1007-15. PubMed ID: 25627091
[TBL] [Abstract][Full Text] [Related]
10. Intracellular bevacizumab reduces phagocytotic uptake in RPE cells.
Klettner A; Möhle F; Roider J
Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):819-24. PubMed ID: 20169356
[TBL] [Abstract][Full Text] [Related]
11. Fucoidan reduces secretion and expression of vascular endothelial growth factor in the retinal pigment epithelium and reduces angiogenesis in vitro.
Dithmer M; Fuchs S; Shi Y; Schmidt H; Richert E; Roider J; Klettner A
PLoS One; 2014; 9(2):e89150. PubMed ID: 24558482
[TBL] [Abstract][Full Text] [Related]
12. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.
Malik D; Tarek M; Caceres del Carpio J; Ramirez C; Boyer D; Kenney MC; Kuppermann BD
Br J Ophthalmol; 2014 Jun; 98 Suppl 1(Suppl 1):i11-16. PubMed ID: 24836865
[TBL] [Abstract][Full Text] [Related]
13. Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions.
Saenz-de-Viteri M; Fernández-Robredo P; Hernández M; Bezunartea J; Reiter N; Recalde S; García-Layana A
Biochem Pharmacol; 2016 Mar; 103():129-39. PubMed ID: 26793998
[TBL] [Abstract][Full Text] [Related]
14. Gene profiling of human VEGF signaling pathways in human endothelial and retinal pigment epithelial cells after anti VEGF treatment.
Golan S; Entin-Meer M; Semo Y; Maysel-Auslender S; Mezad-Koursh D; Keren G; Loewenstein A; Barak A
BMC Res Notes; 2014 Sep; 7():617. PubMed ID: 25201034
[TBL] [Abstract][Full Text] [Related]
15. Effects of bevacizumab, ranibizumab, and aflibercept on phagocytic properties in human RPE cybrids with AMD versus normal mitochondria.
Vo TA; Abedi S; Schneider K; Chwa M; Kenney MC
Exp Eye Res; 2018 Dec; 177():112-116. PubMed ID: 30071215
[TBL] [Abstract][Full Text] [Related]
16. Differences in Uptake and Intracellular Fate between Bevacizumab and Aflibercept after Repetitive Long-Term Treatment in the Retinal Pigment Epithelium.
Borchers L; Roider J; Klettner A
Ophthalmic Res; 2021; 64(3):369-388. PubMed ID: 33011724
[TBL] [Abstract][Full Text] [Related]
17. Combinatory inhibition of VEGF and FGF2 is superior to solitary VEGF inhibition in an in vitro model of RPE-induced angiogenesis.
Stahl A; Paschek L; Martin G; Feltgen N; Hansen LL; Agostini HT
Graefes Arch Clin Exp Ophthalmol; 2009 Jun; 247(6):767-73. PubMed ID: 19247683
[TBL] [Abstract][Full Text] [Related]
18. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.
Spitzer MS; Yoeruek E; Sierra A; Wallenfels-Thilo B; Schraermeyer U; Spitzer B; Bartz-Schmidt KU; Szurman P
Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1837-42. PubMed ID: 17347807
[TBL] [Abstract][Full Text] [Related]
19. Effect of Long-term Anti-VEGF Treatment on Viability and Function of RPE Cells.
Brinkmann A; Winkelmann K; Käckenmeister T; Roider J; Klettner A
Curr Eye Res; 2022 Jan; 47(1):127-134. PubMed ID: 33998943
[TBL] [Abstract][Full Text] [Related]
20. Intracellular pathways following uptake of bevacizumab in RPE cells.
Aboul Naga SH; Dithmer M; Chitadze G; Kabelitz D; Lucius R; Roider J; Klettner A
Exp Eye Res; 2015 Feb; 131():29-41. PubMed ID: 25533679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
